Autonomix Announces Reverse Stock Split
Autonomix (NASDAQ: AMIX) approved a 1-for-21 reverse stock split of its common stock, effective 12:01 a.m. ET on June 24, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autonomix (NASDAQ: AMIX) approved a 1-for-21 reverse stock split of its common stock, effective 12:01 a.m. ET on June 24, 2026. Shares will continue trading on Nasdaq under AMIX with new CUSIP 05330T304.
The split reduces outstanding shares from about 11.4 million to about 543,000, with par value unchanged at $0.001. Fractional shares will not be issued; holders will receive cash instead. Authorized shares remain at 500 million, and equity plan reserves will be proportionately reduced.
Positive
- 1-for-21 reverse stock split effective June 24, 2026
- Outstanding shares reduced from ~11.4 million to ~543,000
- No change to $0.001 par value per share
- Equity compensation plan share reserve reduced proportionately
Negative
- None.
Details
News Market Reaction – AMIX
On Jun 22, the first trading day after this news, AMIX closed 4.28% above the previous close.
Data tracked by StockTitan Argus for the Jun 22 session.
Key Figures
- Reverse split ratio
- 1-for-21
- Common stock reverse split effective June 24, 2026
- Shares outstanding pre-split
- approximately 11.4 million shares
- Common stock before 1-for-21 reverse split
- Shares outstanding post-split
- approximately 543,000 shares
- Common stock after 1-for-21 reverse split
- Authorized shares
- 500 million shares
- Authorized common stock remains unchanged after reverse split
- Accumulated deficit
- $67.1 million
- As of March 31, 2026 (10-K)
- Operating cash flow
- -$12.3 million
- Negative operating cash flow, fiscal 2026 (10-K)
- Net loss
- $14.0 million
- Nine months ended December 31, 2025 (10-Q)
- Additional financing need
- $30–$36 million
- Estimated funding required to reach first commercialization (10-Q)
Historical Context
-
CEO segment highlighting growing scientific and clinical recognition of platform.
-
Clinical data discussion on visceral cancer pain and platform potential.
-
New U.S. patent covering transvascular monitoring and treatment systems.
-
EuroPCR 2026 abstract acceptances on pancreatic cancer pain mitigation data.
-
Digestive Disease Week 2026 abstract on long-term pancreatic cancer pain outcomes.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
reverse stock split financial
cusip financial
par value financial
equity compensation plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, TX, June 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-21 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on June 24, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market on June 24, 2026 on a post-split basis, under the existing ticker symbol “AMIX” but with a new CUSIP number 05330T304.
As a result of the reverse stock split, every 21 shares of the Company’s common stock issued and outstanding prior to the opening of trading on June 24, 2026 will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of
As a result of the reverse stock split, the number of shares of common stock outstanding will be reduced from approximately 11.4 million shares to approximately 543,000 shares, and the number of authorized shares of common stock will remain at 500 million shares. In addition, the number of shares reserved for issuance under the Company’s equity compensation plan immediately prior to the reverse stock split will be reduced proportionately.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.